- Home
- LXP vs KOD Comparison
LXP vs KOD Comparison
Compare LXP & KOD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LXP | KOD |
|---|---|---|
| Founded | 1993 | 2009 |
| Country | United States | United States |
| Employees | 58 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.8B |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | LXP | KOD |
|---|---|---|
| Price | $52.36 | $46.56 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 7 |
| Target Price | ★ $51.88 | $35.43 |
| AVG Volume (30 Days) | 558.9K | ★ 1.9M |
| Earning Date | 04-29-2026 | 05-13-2026 |
| Dividend Yield | ★ 5.42% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $6.00 | N/A |
| P/E Ratio | $26.35 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.61 | $3.31 |
| 52 Week High | $52.52 | $46.67 |
Technical Indicators
Market Signals| Indicator | LXP | KOD |
|---|---|---|
| Relative Strength Index (RSI) | 71.29 | 66.54 |
| Support Level | $45.75 | $21.82 |
| Resistance Level | $52.48 | N/A |
| Average True Range (ATR) | 1.13 | 3.83 |
| MACD | 0.56 | 0.23 |
| Stochastic Oscillator | 96.67 | 92.16 |
Price Performance
Historical ComparisonAbout LXP LXP Industrial Trust (Maryland REIT)
LXP Industrial Trust is a real estate investment trust principally involved in the ownership of equity and debt investments in single-tenant properties and land throughout the United States. The majority of the revenue is earned through rental revenue.
About KOD Kodiak Sciences Inc
Kodiak Sciences Inc has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) platform, for retinal medicines. Its investigational medicine, tarcocimab tedromer (Zenkuda or tarcocimab), is an anti-VEGF therapy built on Kodiak's proprietary ABC platform. Another investigational medicine, KSI-501, is an anti-interleukin 6, or IL-6, VEGF-trap bispecific therapy built on the ABC platform and is being developed for high-prevalence retinal vascular diseases and intended to address the unmet needs of extended durability and targeting disease biology beyond VEGF for differentiated efficacy. Its third investigational medicine, KSI-101, is a high-strength (100 mg/mL) bispecific protein targeting IL-6 and VEGF.